Back to top
more

Anika Therapeutics (ANIK)

(Delayed Data from NSDQ)

$8.25 USD

8.25
85,305

-0.10 (-1.20%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $8.25 0.00 (0.00%) 6:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Concert's (CNCE) CTP-656 Gets Orphan Drug Status in U.S.

by Zacks Equity Research

Concert Pharmaceuticals, Inc. (CNCE) announced that the FDA has granted orphan drug designation to its candidate CTP-656 for the treatment of cystic fibrosis.

    Zacks Equity Research

    Bristol-Myers Settles Litigation with Merck for Keytruda

    by Zacks Equity Research

    Bristol-Myers Squibb Company (BMY) along with partner Ono Pharmaceutical Company, Ltd. announced that both the companies have signed a global patent license agreement with Merck & Co., Inc. (MRK) to settle all litigation related to Keytruda.

      Zacks Equity Research

      Minerva Presents Additional Data from Schizophrenia Drug

      by Zacks Equity Research

      Minerva Neurosciences, Inc. (NERV) announced the results of additional data analyses from phase IIb clinical trial of MIN-101, as monotherapy in patients with negative symptoms of schizophrenia.

        Zacks Equity Research

        Shire's (SHPG) ADHD Candidate's NDA Accepted by FDA

        by Zacks Equity Research

        Shire plc (SHPG) announced that the FDA has acknowledged receipt of the Class 2 resubmission of a New Drug Application (NDA) for pipeline candidate, SHP465.

          Zacks Equity Research

          Bristol-Myers to Not Seek Accelerated Approval for Opdivo+Yervoy

          by Zacks Equity Research

          Bristol-Myers (BMY) won't seek an accelerated approval in the U.S. for the combination of its two immuno-oncology treatments Opdivo plus Yervoy for the first-line lung cancer.

            Zacks Equity Research

            Aduro (ADRO) Inks License Agreement with Stanford University

            by Zacks Equity Research

            Aduro Biotech, Inc. (ADRO) announced that it has inked an exclusive license agreement with Stanford University for state-of-the-art neo-antigen identification technology.

              Zacks Equity Research

              Mallinckrodt to Pay $100M Fine to FTC for Questcor Matter

              by Zacks Equity Research

              Mallinckrodt plc (MNK), will have to pay a fine of $100 million to the U.S. Federal Trade Commission (FTC) to resolve the latter???s investigation into the acquisition of Synacthen Depot by its Questcor division.

                Zacks Equity Research

                Apricus (APRI) Stock Gains on Vitaros' Approval in Mexico

                by Zacks Equity Research

                Apricus (APRI) announced that Vitaros was approved in Mexico for the treatment of patients with erectile dysfunction.

                  Zacks Equity Research

                  Teva's (TEVA) Pain Drug Vantrela ER Receives FDA Approval

                  by Zacks Equity Research

                  Teva Pharmaceutical Industries Ltd. (TEVA) announced that the FDA has approved Vantrela ER for the treatment of pain which is severe enough to require daily, around-the-clock, long-term opioid treatment.

                    Zacks Equity Research

                    Bioblast (ORPN) SCA3 Drug Favorable in Phase IIa Study

                    by Zacks Equity Research

                    Bioblast (ORPN) announced results from a phase IIa study on trehalose for the treatment of patients with spinocerebellar ataxia type 3.

                      Zacks Equity Research

                      Allergan's Uterine Fibroids Candidate Positive in Phase III

                      by Zacks Equity Research

                      Allergan Plc (AGN) and European specialty pharma company Gedeon Richter reported encouraging results from a phase III study on their pipeline candidate, ulipristal acetate, in women with abnormal bleeding due to uterine fibroids.

                        Zacks Equity Research

                        Concert Offers Update on Cystic Fibrosis Drug, Stock Down

                        by Zacks Equity Research

                        Concert Pharmaceuticals, Inc. (CNCE) provided update on the development plan of its next generation CFTR potentiator, CTP-656, for the treatment of cystic fibrosis in the U.S. and Europe.

                          Zacks Equity Research

                          Sanofi Diabetes Drug Suliqua Wins EU Marketing Approval

                          by Zacks Equity Research

                          Sanofi (SNY) announced that the European Commission has granted marketing authorization to its once-daily injection, Suliqua a combination of diabetes drugs Lantus and lixisenatide for the treatment of diabetes.

                            Zacks Equity Research

                            Jazz Begins Phase III Study for Label Expansion of Defitelio

                            by Zacks Equity Research

                            Jazz Pharmaceuticals Public Limited Company (JAZZ) announced the initiation of a phase III clinical study on its marketed drug, Defitelio (defibrotide), for the potential prevention of veno-occlusive disease.

                              Zacks Equity Research

                              AstraZeneca Offers Update on Immuno-Oncology Program

                              by Zacks Equity Research

                              AstraZeneca (AZN) provided an update on its late-stage immuno-oncology program for first-line NSCLC.

                                Zacks Equity Research

                                Agenus, NCI Ink Deal to Evaluate Prophage-Keytruda Combo

                                by Zacks Equity Research

                                Agenus (AGEN) entered into a clinical trial collaboration with the National Cancer Institute to evaluate Prophage, in conjunction with Merck's (MRK) Keytruda.

                                  Zacks Equity Research

                                  Kura Oncology Starts Dosing Patients in Phase II CMML Study

                                  by Zacks Equity Research

                                  Kura Oncology (KURA) dosed the first patient in a phase II study on tipifarnib for the treatment of chronic myelomonocytic leukemia.

                                    Zacks Equity Research

                                    Benitec Stock Up on Orphan Drug Status for BB-301 in EU

                                    by Zacks Equity Research

                                    Benitec (BNTC) announced that its proposed candidate, BB-301, received Orphan Drug Designation in the EU for the treatment of ocularpharyngeal muscular dystrophy.

                                      Zacks Equity Research

                                      Biogen to Pay $1.25B to Forward Pharma in Tecfidera Lawsuit

                                      by Zacks Equity Research

                                      Biogen Inc. (BIIB) recently entered into a settlement and license agreement with Danish biotech, Forward Pharma A/S (FWP) with respect to an ongoing patent dispute for Tecfidera.

                                        Zacks Equity Research

                                        Biogen's Multiple Sclerosis Franchise to Drive Growth in 2017

                                        by Zacks Equity Research

                                        We issued an updated research report on Biogen Inc. (BIIB) on Jan 16.

                                          Zacks Equity Research

                                          What's Behind Clovis' (CLVS) One-Year Rally of 146.3%?

                                          by Zacks Equity Research

                                          In December, Clovis received the FDA nod for its first product, Rubraca, which sent its shares soaring.

                                            Zacks Equity Research

                                            Novartis to Conduct Trial on Obese, Type II Diabetes Patients

                                            by Zacks Equity Research

                                            In a recent announcement, MorphoSys AG mentioned that its partner Swiss major Novartis AG (NVS) will conduct a phase II clinical trial on pipeline candidate bimagrumab in obese patients with type II diabetes.

                                              Zacks Equity Research

                                              Pluristem (PSTI) Intermittent Claudication Study Enrolled

                                              by Zacks Equity Research

                                              Pluristem Therapeutics (PSTI) has completed patient enrollment in a phase II study on PLX-PAD cells for the treatment of intermittent claudication.

                                                Zacks Equity Research

                                                Incyte/Merck to Start More Epacadostat-Keytruda Studies

                                                by Zacks Equity Research

                                                Incyte (INCY) and Merck (MRK) announced that they have decided to initiate additional pivotal studies on epacadostat, in combination with Merck's Keytruda.

                                                  Zacks Equity Research

                                                  AMAG, Palatin Ink Deal to Focus on Female Sexual Disorder

                                                  by Zacks Equity Research

                                                  AMAG (AMAG) announced that it has entered into an agreement with Palatin (PTN) for the exclusive U.S. rights to develop and commercialize Rekynda.